+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07291323

Phase 1 Study Evaluating Safety and Dosage of JANX011 in Healthy Adults Aged 18 to 65

Led by Janux Therapeutics · Updated on 2026-04-23

60

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying JANX011, a drug being tested in healthy adult volunteers to understand its safety, tolerability, how it moves through the body pharmacokinetics, and how it affects the body pharmacodynamics. This early-phase, first-in-human study aims to gather information that could help understand its potential use for patients with autoimmune diseases. Participants will receive JANX011 by a single subcutaneous injection, with doses increasing across groups to find the maximum dose that can be tolerated. The study may also involve intravenous dosing if needed. This open-label trial involves a dose escalation approach where participants receive one dose and are monitored before the next dose is tested. During the study, volunteers will be closely monitored for any treatment-emergent adverse events, serious adverse events, and events of special interest for up to 85 days. Assessments include physical exams, lab tests, and medical history reviews to ensure safety. Participants will provide written informed consent before joining, and the study is designed to evaluate JANX011s effects in healthy adults aged 18 to 65 years over the course of the trial.

CONDITIONS

Brief Title

Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.

Research Team

J

Janux Therapeutics

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here